Companies
/Healthcare
Novavax Inc
$7.86
▼ $0.11 (−1.32%) today
Markets open · 10:50am ET
Novavax (NVAX) Earnings History & Trends
86%
EPS beat rate
+204.38%
Avg. EPS surprise
Consecutive EPS beats
NVAX vs Market · 30-day return after each reportNVAXS&P 500
NVAX EPS Trend · estimate vs actualEstimateActual
NVAX Revenue Trend · estimate vs actualEstimateActual
How Often Does Novavax Beat Earnings Estimates?
Novavax beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 4 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Quarter includes $11 million in non-cash deferred royalty recognition related to prior Nuvaxovid sales by SK bioscience to the South Korean government; no non-GAAP EPS disclosed. | $-0.19 est. $-0.35 | +45.09% | $68.3M est. $50.4M | +35.45% |
| Q2 2026 | $-0.32 est. $-0.38 | +16.58% | $56.7M est. $53.3M | +6.38% |
| Q1 2026 | $-0.06 est. $-0.23 | +73.46% | $139.5M est. $81.0M | +72.27% |
| Q4 2025 | $0.11 est. $-0.49 | +122.48% | $147.1M est. $89.9M | +63.75% |
| Q3 2025 | $-1.25 est. $-0.92 | −36.36% | $70.4M est. $44.9M | +56.99% |
| Q2 2025 | $0.62 est. $-0.08 | +895.89% | $239.2M est. $165.0M | +44.98% |
| Q1 2025 | $2.93 est. $0.71 | +313.55% | $666.7M est. $343.9M | +93.88% |
Figures from SEC filings and company reports. Not investment advice.